• Philadelphia, PA (July 30, 2019) – Oncoceutics, Inc. announced that a series of presentations at the 2019 DIPG/DMG Symposium to be held August 2-3 in Sydney, Australia, will highlight ONC201 as a promising treatment for specific types of lethal brain cancer. These presentations are part of a session describing progress in new drug development for diffuse midline gliomas (DMG), which includes diffuse intrinsic pontine glioma (DIPG).

    The first of the ONC201-related talks will describe the clinical experience with ONC201, the first small molecule DRD2 antagonist for oncology, in pediatric patients with gliomas containing a specific mutation, called H3 K27M, that has a high prevalence in DMGs and DIPGs. Sharon Gardner, MD, New York University, who is the principal investigator of the clinical trial, will present the clinical data. The next talk will feature William Hoos, CCO of XCures, who will present on the topic of innovative trial designs, which will highlight the partnership between Oncoceutics and XCures that enables efficient clinical research and data collection in ultra-rare diseases. Wolfgang Oster, MD, PhD, CEO and Chairman of Oncoceutics, will provide an industry perspective on drug development for DMGs as part of the same session on August 3rd.

    These presentations report results from systematic clinical studies with ONC201 combined with a real-life experience gathered in an Expanded Access Program (EAP), when patients are not able to enroll on a clinical protocol but fulfill a narrowly defined set of characteristics that mimic the ones in clinical studies. Ongoing and planned clinical programs with ONC201 for DIPG and DMG were presented on June 20, 2019 at the Pediatric Subcommittee of the FDA’s Oncology Drugs Advisory Committee. A webcast recording of this event can be viewed at the following link (required Adobe Connect): https://collaboration.fda.gov/ptqmoswmcnep/

    A team of Oncoceutics members will be present at the conference in Sydney. If you have any questions please contact us at info@oncoceutics.com.

     

    About Oncoceutics

    Oncoceutics, Inc. is a clinical-stage drug discovery and development company with a novel class of compounds, called “imipridones,” that selectively target G protein-coupled receptors for oncology. The first lead compound to emerge from this program is ONC201, an orally active small molecule DRD2 antagonist. The company is supported by grants from NCI, FDA, Musella Foundation, and a series of private and public partnerships. Visit Oncoceuticsor contact Press@oncoceutics.comfor more information.

Photostream